S

    Sight Sciences Inc (SGHT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $8.55
    +0.14 (+1.66%)

    Market Cap: $468.25M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    -7.05%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.15 - $-0.09
    5 analysts
    EPS Revisions
    3
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-0.16-25.7%
    60d ago$-0.16-25.7%
    30d ago$-0.16-25.7%
    7d ago$-0.15-16.2%
    Current$-0.13
    Revenue Consensus
    $24M
    Range$23M - $24M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.17 - $0.19
    5 analysts
    Revenue Consensus
    $27M
    Range$26M - $27M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 5
    		$-0.08$-0.15+46.67%Beat+65.2%
    Mar 26
    Reported May 6
    		$-0.24$-0.20-20.00%Miss+14.3%
    Dec 25
    Reported Mar 4
    		$-0.08$-0.15+47.68%Beat+65.2%
    Sep 25
    Reported Nov 6
    		$-0.16$-0.26+38.46%Beat+27.3%
    Jun 25
    Reported Aug 7
    		$-0.23$-0.25+8.00%Beat+8.0%
    Mar 25
    Reported May 8
    		$-0.28$-0.23-21.74%Miss+3.4%
    Dec 24
    Reported Mar 5
    		$-0.23$-0.18-30.68%Miss-4.5%
    Sep 24
    Reported Nov 7
    		$-0.22$-0.21-4.76%Miss+18.5%
    Jun 24
    Reported Aug 1
    		$-0.25$-0.30+16.67%Beat+16.7%
    Mar 24
    Reported May 2
    		$-0.29$-0.28-3.57%Miss+17.1%
    Dec 23
    Reported Mar 7
    		$-0.22$-0.32+31.25%Beat+37.1%
    Sep 23
    Reported Nov 7
    		$-0.27$-0.33+18.18%Beat+41.3%
    Jun 23
    Reported Aug 3
    		$-0.30$-0.34+11.76%Beat+40.0%
    Mar 23
    Reported May 4
    		$-0.35$-0.39+10.26%Beat+28.6%
    Dec 22
    Reported Mar 13
    		$-0.35$-0.42+16.67%Beat-2.9%
    Sep 22
    Reported Nov 10
    		$-0.46$-0.46+0.00%Beat-7.0%
    Jun 22
    Reported Aug 11
    		$-0.50$-0.42-19.05%Miss+72.7%
    Mar 22
    Reported May 10
    		$-0.49$-0.40-22.50%Miss+62.0%
    Dec 21
    Reported Mar 24
    		$-0.34$-0.39+12.82%Beat+86.8%
    Sep 21
    Reported Nov 10
    		$-0.43$-0.37-16.22%Miss+77.9%
    Jun 21
    Reported Jul 15
    		$-1.83$-1.72-6.40%Miss-
    Mar 21
    Reported Jun 2
    		$-1.29$-0.35-268.57%Miss-
    Dec 20
    Reported Mar 31
    		$-2.57$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-1.94$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-15.27EV/EBITDA-4.25x
    Price/FCF-19.71xFCF Yield-5.07%
    Profitability
    Profit Margin-35.70%Operating Margin-16.60%
    ROE-48.40%ROIC-29.70%
    Financial Health
    Debt/Equity0.77xInterest Coverage-5.41x
    Current Ratio4.95xQuick Ratio4.67x
    Trading Statistics
    Beta2.42Avg Volume301.77K
    52-Week High$9.2452-Week Low$3.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.34
    SMA 20$7.74
    SMA 50$6.26
    SMA 200$5.82
    EMA 10$8.24
    EMA 20$7.71
    EMA 50$6.64
    EMA 200$5.46

    MACD

    Line: 0.72Signal: 0.74Hist: -0.02

    ADX

    ADX: 41.2+DI: 32.5-DI: 11.6

    Aroon & PSAR

    Aroon Up72.0
    Aroon DownN/A
    PSAR$8.77

    Bollinger Bands

    Upper Band$9.75
    Lower Band$5.74
    %B Position5177%(Upper)
    Band Width0.70

    RSI (14-Day)

    Overbought
    76.4

    Momentum Oscillators

    Stoch %K72.5
    Stoch %D76.3
    Williams %R-24.1
    ROC (10d)5.0%
    Momentum0.41
    CCI (20d)64.3
    MFI (14d)66.0

    Volatility Measures

    ATR (14d)$0.39(4.6%)
    StdDev (20d)1.00
    Hist Vol102.2%(High)

    Volume Flow

    VWAP$8.47
    OBV7.7M
    AD Line697.7K
    CMF (20d)0.120

    Volume Metrics

    Avg Vol (20d)323.0K
    Vol Ratio0.4x(Low)
    VWMA (20d)$7.51

    Pivot Points

    R3$8.85
    R2$8.70
    R1$8.56
    Pivot Point$8.40
    S1$8.26
    S2$8.10
    S3$7.96

    Advanced Oscillators

    TSI53.10
    Ultimate Osc55.9
    KST521.35

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$23.39M$19.70M$20.39M$19.91M$19.56M$17.51M$19.07M$20.16M$21.37M$19.27M$18.75M$20.01M
    Cost of Revenue$2.01M$2.72M$2.60M$2.71M$2.98M$2.41M$2.51M$3.25M$3.02M$2.79M$2.77M$2.68M
    Gross Profit$21.37M$16.98M$17.79M$17.20M$16.59M$15.09M$16.56M$16.91M$18.34M$16.47M$15.98M$17.33M
    Operating Expenses$25.26M$29.39M$21.46M$25.10M$28.25M$28.95M$28.49M$28.14M$31.00M$31.20M$27.09M$30.74M
    R&D$2.51M$2.55M$2.44M$3.35M$4.39M$4.43M$4.29M$4.75M$4.32M$4.64M$3.43M$4.24M
    SG&A$22.75M$26.84M$19.02M$21.75M$23.87M$24.52M$24.20M$23.39M$26.68M$26.56M$23.66M$26.50M
    Operating Income$-3,888,000$-12,413,000$-3,668,000$-7,905,000$-11,667,000$-13,859,000$-11,929,000$-11,229,000$-12,651,000$-14,723,000$-11,108,000$-13,411,000
    Interest Income$678,000$741,000$834,000$965,000$1.03M$1.15M$1.29M$1.45M$1.53M$1.65M$1.79M$1.90M
    Interest Expense$1.29M$1.27M$1.29M$1.31M$1.28M$1.26M$1.16M$1.15M$1.15M$3.17M$1.35M$1.43M
    Income Before Tax$-4,418,000$-12,969,000$-4,154,000$-8,248,000$-11,901,000$-14,113,000$-11,808,000$-10,900,000$-12,314,000$-16,249,000$-10,681,000$-12,957,000
    Income Tax Expense$28,000$11,000$8,000$-79,000$40,000$41,000$38,000$166,000$15,000$17,000$10,000$78,000
    Net Income$-4,446,000$-12,980,000$-4,162,000$-8,169,000$-11,941,000$-14,154,000$-11,846,000$-11,066,000$-12,329,000$-16,266,000$-10,691,000$-13,035,000
    EBITDA$-3,469,000$-12,106,000$-3,361,000$-7,553,000$-11,281,000$-13,621,000$-11,556,000$-10,663,000$-12,435,000$-14,445,000$-10,798,000$-13,104,000
    EBIT$-3,806,000$-12,442,000$-3,699,000$-7,907,000$-11,643,000$-13,998,000$-11,935,000$-11,203,000$-12,695,000$-14,731,000$-11,119,000$-13,422,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SGHT

    News

    FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

    Sight Sciences, Inc. announced that the FDA has expanded the indications for use for its TearCare System, making it the first and only treatment for meibomian gland dysfunction (MGD) indicated to improve meibomian gland function in adult patients with evaporative dry eye disease. This expansion highlights the system's ability to address the underlying cause of dry eye by improving gland function, rather than just managing symptoms. The TearCare System uses targeted thermal energy and clinician-directed expression to clear gland obstructions.

    VisionMonday.com•8/20/26•
    Bullish

    Sight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye Disease

    Sight Sciences, Inc. announced that the FDA has expanded the indications for its TearCare® System, allowing it to be used for improving meibomian gland function in adult patients with evaporative dry eye disease caused by meibomian gland dysfunction (MGD). This makes TearCare the first treatment specifically indicated to enhance gland function in such patients, addressing the underlying causes of dry eye disease. The updated indication provides a clinically meaningful endpoint for eye care providers and reinforces Sight Sciences' commitment to innovative treatments.

    Quiver Quantitative•8/19/26•
    Bullish

    GSA Capital Partners LLP Makes New Investment in Sight Sciences, Inc. $SGHT

    GSA Capital Partners LLP has made a new investment in Sight Sciences, Inc. (NASDAQ:SGHT), purchasing 167,564 shares valued at $908,000. This investment gives GSA Capital Partners LLP a 0.31% stake in the company, with institutional investors collectively owning 55.51% of SGHT. Despite the company exceeding quarterly earnings expectations, analysts have mixed ratings, with an average "Hold" rating and a target price of $7.88.

    MarketBeat•8/19/26•
    Neutral

    A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12

    This article provides a quick overview of analyst ratings for Sight Sciences (SGHT.US), indicating a forecast share price between $8 and $12. It likely includes details on recent analyst actions and potential price targets for the company.

    Moomoo•8/19/26•
    Neutral

    Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares

    A shareholder of Sight Sciences (NASDAQ: SGHT), Jeremy Hayden, plans to sell 12,014 shares of common stock through Fidelity Brokerage Services LLC on or after August 17, 2026, with an estimated market value of $97,841.48. This filing also details previous sales by Hayden in July and August 2026 and notes that some of the shares originated from restricted stock vesting granted as compensation. The information is derived from a Form 144 SEC filing, which is used for transparency in large stock sales.

    Stock Titan•8/17/26•
    Neutral

    Frequently Asked Questions About SGHT

    Does SGHT pay dividends?
    Sight Sciences Inc (SGHT) does not currently pay a regular dividend.
    What is SGHT's market cap?
    Sight Sciences Inc (SGHT) has a market capitalization of $468.25M with a current stock price of $8.55.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In